SCHEMBL4860414

SCHEMBL4860414

C=CCON=C1CN(C(=O)OC(C)(C)C)Nc2ccccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.38
ALDH1A1 P00352 3/20 0.33
HPGD P15428 2/20 0.33
CCNB2 O95067 1/20 0.32
CDK1 P06493 1/20 0.32
CCNB1 P14635 1/20 0.32
GSK3B P49841 1/20 0.32
CCNB3 Q8WWL7 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
CYP3A4 P08684 1/20 0.32
NAMPT P43490 1/20 0.31
BRD4 O60885 2/20 0.31
CREBBP Q92793 2/20 0.31
CYP19A1 P11511 1/20 0.31
USP8 P40818 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PTGS2 P35354 1/20 0.31
BCHE P06276 1/20 0.30
KDM4E B2RXH2 1/20 0.30
GLA P06280 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14196720 1.00 MAPK1 (0.38) MAPK1ALDH1A1HPGDCCNB2CDK1
SCHEMBL4865746 0.90 NPSR1 (0.37) MAPK1ALDH1A1HPGDNPSR1CYP3A4
SCHEMBL14224313 0.90 NPSR1 (0.37) MAPK1ALDH1A1HPGDNPSR1CYP3A4
SCHEMBL14425277 0.89 MAPK1 (0.40) MAPK1ALDH1A1CCNB2CDK1CCNB1
SCHEMBL5321196 0.85 CYP3A4 (0.35) ALDH1A1NPSR1CYP3A4USP8MEN1
SCHEMBL5321199 0.85 CYP3A4 (0.35) ALDH1A1NPSR1CYP3A4USP8MEN1
SCHEMBL4863074 0.85 MAPK1 (0.39) MAPK1HPGDCCNB2CDK1CCNB1
SCHEMBL14196714 0.85 MAPK1 (0.39) MAPK1HPGDCCNB2CDK1CCNB1
SCHEMBL4856100 0.84 MAPK1 (0.38) MAPK1CCNB2CDK1CCNB1GSK3B
SCHEMBL14438933 0.79 PTGS2 (0.31) PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365071-B2 Heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as β-lactamase inhibitors and antibacterials AVENTIS PHARMA S.A. (FR) 2008-04-29 US disclosed
US-20040097490-A1 Novel heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as B-lactamase inhibitors and antibacterials AVENTIS PHARMA S.A. (FR) 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097490-A1 Novel heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as B-lactamase inhibitors and antibacterials GAA, BBOX1, BPGM MAPK1 1623/4885ALDH1A1 323/4885HPGD 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.